1. Introduction {#sec1}
===============

Among men in Western industrialized countries, prostate cancer (PC) is the most frequently diagnosed malignant disease and the second leading cause of cancer-specific mortality.[@bib1] In Japan, the incidence of PC has markedly increased in recent years, and 21% of PC patients present with distant metastases; 19% present with locally advanced disease at diagnosis.[@bib1], [@bib2] With this high incidence of advanced disease, androgen-deprivation therapy (ADT) is a mainstay of treatment for locally advanced and metastatic PC. ADT is reported to be effective for \<  3--5 years as an average interval,[@bib3], [@bib4] but cases of castrated PC eventually transform into castration-resistant PC (CRPC).

Docetaxel, which is the current standard first-line chemotherapeutic agent for CRPC, has shown survival and palliative benefits in the TAX327 and the Southwest Oncology Group 99-16 studies.[@bib5], [@bib6] Several new agents such as abiraterone, enzalutamide, and cabazitaxel were shown to have a survival benefit against CRPC in Phase 3 trials.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11] However, the optimal sequencing of treatment for CRPC patients has not yet been established.

The classical secondary hormonal therapies (SHTs) such as corticosteroids and estramustine phosphate (EMP) are described as options for first-line systemic therapy for CRPC without visceral metastases in the National Comprehensive Cancer Network Clinical Practice Guidelines for Prostate Cancer, version 1.2015.[@bib12] However, Armstrong et al[@bib13] demonstrated that the prior use of EMP is a risk factor for the survival of CRPC patients undergoing docetaxel therapy. Although there is insufficient data supporting the classical SHTs as first-line systemic therapy for CRPC, it may be true that the majority of CRPC patients should be administered docetaxel therapy prior to SHTs before receiving any of the emerging new agents in Japan.

Therefore, in the present study we investigated whether classical SHTs could affect the response to docetaxel therapy and the survival of CRPC patients. We also analyzed the clinical factors that could be used to determine whether or not classical SHTs are feasible prior to docetaxel therapy in CRPC patients.

2. Materials and methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

Between 2005 and 2011, a total of 73 patients who received docetaxel therapy at four hospitals in Ibaraki prefecture, Japan were enrolled in this multi-institution retrospective cohort study. The eligible patients had histologically confirmed adenocarcinoma of the prostate, as clinically diagnosed CRPC. The Prostate Cancer Clinical Trials Working Group advises classifying tumors that are progressing with castration levels of testosterone as "castration-resistant".[@bib14] We defined CRPC by disease progression after the administration of ADT, because the serum levels of testosterone of some patients were not measured. Disease progression was defined by prostate-specific antigen (PSA) progression or by radiographic imaging studies. PSA progression was defined as an increase by ≥ 25% in serum PSA (at least 2 ng/mL) from the nadir value.

We evaluated the results of the patients\' radiographic imaging studies using the Response Evaluation Criteria in Solid Tumors version 1.1. We excluded the patients who had prior treatment with cytotoxic agents other than EMP from this study. To analyze the differences in CRPC treatment types, we divided the patients into two groups. The patients who underwent docetaxel therapy as the initial treatment for CRPC were classified as the DOC group. After the initial docetaxel therapy, these patients underwent other treatment, e.g., with SHTs, other chemotherapy, and best supportive care. The patients who underwent docetaxel therapy after classical SHTs were classified as the SHTs-DOC group.

The data at the diagnosis of CRPC included the patient\'s age, performance status, presence of pain, laboratory evaluations (hemoglobin, alkaline phosphatase, and PSA), and site of metastases. The follow-up status data were collected in March 2016. The median duration of follow-up was 23.4 months (range, 1.53--101.2 months). The institutional review board of four hospitals approved this study, as the registry form was anonymous.

2.2. Evaluation of PSA doubling time {#sec2.2}
------------------------------------

The PSA doubling time (PSADT) was defined as the time required for the PSA level to double. The PSADT was estimated according to the following formula:where ln is the natural log, and T is the number of months between two consecutive PSA determinations (PSA~1~ and PSA~2~).[@bib15] PSA~1~ is the value at the time of the diagnosis of CRPC, and PSA~2~ is the value at the start of the initial treatment for CRPC. The PSADTs were determined by two measurements of the PSA value at least 4 weeks apart.

2.3. Treatment {#sec2.3}
--------------

The docetaxel therapy was given in a regimen of every 3 weeks docetaxel (70--75 mg/m^2^) based on the schedule reported by Tannock et al,[@bib5] and 5-mg prednisone was generally administered twice daily. The adjustment of the treatment schedule and any dose reduction in docetaxel therapy were determined by the treating physician\'s recommendation. The agent of classical SHTs was defined as low-dose steroid (prednisone 10 mg/d or dexamethasone 0.5--1.5 mg/d) and EMP.

2.4. Statistical analysis {#sec2.4}
-------------------------

The primary objective of this study was defined as the cause-specific survival (CSS) after either the induction of docetaxel therapy or the time point of the diagnosis of CRPC between the SHTs-DOC group and the DOC group. Survival curves were constructed using the Kaplan--Meier method, and the difference between the curves was evaluated using the Log Rank test. As the secondary objective, we analyzed prognosis-related risk factors in the SHTs-DOC group with univariate and multivariate analysis using Cox\'s proportional hazards model and the Log Rank test. We selected the known prognostic factors for multivariate analysis with the following conditions, i.e., the factors could be assessed in all patients and were not confounder with the variables detected by univariate analysis. We then investigated the differences in the CSS from the time point of the diagnosis of CRPC classified by a combination of significant factors according to the above statistics. Additionally, we analyzed the difference in PSA responses between the DOC group and the SHTs-DOC group by Fisher\'s exact test. "PSA response" was defined as a \>  50% decline following docetaxel therapy compared with the pretreatment PSA. Differences between the two patient groups in baseline characteristics were analyzed with the Chi-square test or Wilcoxon rank sum test. A probability (*P*) value \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Patient characteristics {#sec3.1}
----------------------------

Among the 73 enrolled patients, 26 patients underwent docetaxel therapy (the DOC group), and 47 patients underwent SHTs (the SHTs-DOC group) as the initial treatment for CRPC. The characteristics of the enrolled patients are summarized in [Table 1](#tbl1){ref-type="table"}. Most of the patients in this cohort undertook an alternative antiandrogen therapy and antiandrogen withdrawal. No significant difference in patient characteristics was observed between the DOC and SHTs-DOC groups.

3.2. Analysis of PSA responses and CSS following docetaxel therapy {#sec3.2}
------------------------------------------------------------------

The PSA responses to docetaxel therapy were significantly higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%, *P* = 0.0066; [Fig. 1](#fig1){ref-type="fig"}A). Moreover, the median CSS from starting docetaxel therapy was longer in the DOC group than that in the SHTs-DOC group, but the difference was not significant (23.4 months vs. 16.6 months, *P* = 0.0969; [Fig. 1](#fig1){ref-type="fig"}B).

3.3. Analysis of CSS from time of diagnosis of CRPC {#sec3.3}
---------------------------------------------------

The median CSS from the time of diagnosis of CRPC was not significantly different between the two groups (DOC group 23.4 months, SHTs-DOC group 24.7 months, *P* = 0.9233; [Fig. 2](#fig2){ref-type="fig"}). The univariate analysis to analyze the prognosis-related risk factors in the SHTs-DOC group identified visceral metastasis and pain as significant factors associated with CSS ([Table 2](#tbl2){ref-type="table"}). There were no significant prognosis-related risk factors in multivariate analysis, but the hazard ratio of visceral metastasis and pain was still higher compared with the other factors.

The following statistics with risk classification, assessed by visceral metastasis and/or pain in the SHTs-DOC group, demonstrated that the median CSS form the diagnosis of CRPC was significant shorter in the high-risk group compared with the low-risk group (16.8 months vs. 31.5 months, *P* = 0.0053; [Fig. 3](#fig3){ref-type="fig"}). In low-risk group, the median CSS from the time of diagnosis of CRPC was not significantly different between the DOC group and SHTs-DOC group (31.5 months vs. 31.5 months, *P* = 0.9139; data not shown).

4. Discussion {#sec4}
=============

Docetaxel-based chemotherapy showed a survival benefit for CRPC patients in the TAX327 and the Southwest Oncology Group 99-16 studies.[@bib5], [@bib6] Although the efficacy of the new agents for CRPC has been demonstrated in recent years, docetaxel is still standard as a first-line chemotherapy agent for CRPC patients. However, there is no high-level evidence regarding which type(s) of patients with CRPC should be administered docetaxel-based chemotherapy earlier. In the present study, although survival after DOC therapy in the patients with prior SHTs was shorter than that of the patients without prior SHTs, the initial treatment by docetaxel or SHTs did not result in a significant difference in CSS from the diagnosis of CRPC.

Song et al[@bib16] also assessed the efficacy of initial treatment in 384 CRPC patients by EMP, docetaxel, and mitoxantrone in Korea, and they found that the overall survival from the start of the initial treatment for CRPC was not significantly different among these initial treatments. Therefore, there might be survival benefits of classical SHTs as initial treatment for at least some Asian CRPC patients in clinical practice.

The recent use of AR-axis-targeted (ARAT) therapies, such as abiraterone and enzalutamide, provided improved survival in patients with metastatic CRPC who received prior docetaxel treatment and in those who were chemotherapy-naïve.[@bib8], [@bib10] These clinical benefits of ARAT therapies have been shown in trials of asymptomatic or minimally symptomatic patients. In a systemic review of CRPC treatment, Chi et al[@bib17] suggested the following treatment algorithm for CRPC patients based on prospective/retrospective data and clinical experiences. In their algorithm, ARAT therapies are preferred for patients without the following clinical characteristics: prior ADT response of \< 1 year, symptomatic disease, or visceral disease.

In the present study, the median CSS achieved by administering classical SHTs prior to docetaxel was significantly longer in the CRPC patients who did not have pain and visceral metastases. CRPC is not curable, and so therapeutic strategies should be considered from a viewpoint of optimizing a patient\'s quality of life (QOL). We could not compare QOL between the DOC group and SHTs-DOC group in this retrospective study. However, the prechemotherapy phase is important because the adverse events of chemotherapeutic agents such as docetaxel and cabazitaxel reduce a patient\'s QOL. We thus speculate that SHTs including ARAT therapies are suitable for treating CRPC patients without pain and visceral metastases, particularly in Asian patients including Japanese. In classical SHTs, estrogen agents such as EMP and diethylstilbestrol are associated with cardiovascular and thromboembolic complications.[@bib18], [@bib19] Notably, ARAT therapies are more than 10 times as expensive as classical SHTs in Japan.

The limitations of this study are that it was a retrospective study with a small sample size, and the heterogeneous background of the patients. Missing laboratory data may have influenced the results. In some patients, we were not able to determine whether the inclusion criteria for the CRPC definition were fulfilled because the serum level of testosterone was not checked. The patients in this study were treated upon their clinician\'s recommendation. Furthermore, we could not assess the measurements of patient\'s QOL in this cohort. A prospective study would be necessary to resolve these limitations in future studies.

In conclusion, the early administration of docetaxel improved the PSA response of CRPC patients and their survival after starting docetaxel therapy, but a significant difference in survival after the diagnosis of CRPC was not observed between the patients with early and late initiation of docetaxel therapy. Moreover, there was good survival outcome in the patients without pain and visceral metastases, even among those treated by classical SHTs prior to docetaxel.
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![Analysis of prostate-specific antigen (PSA) responses and cause-specific survival (CSS) following docetaxel therapy. (A) PSA responses \[\> 50% PSA decline compared with pretreatment PSA following docetaxel (DOC) therapy\] and (B) CSS from the start of DOC therapy in the DOC group and secondary hormonal therapies (SHTs)-DOC group. \* Statistically significant difference (*P* \< 0.05). pts., patients.](gr1){#fig1}

![Kaplan--Meier estimates of cause-specific survival (CSS) in the secondary hormonal therapies-docetaxel (SHTs-DOC) group and DOC group. CRPC, castration-resistant prostate cancer.](gr2){#fig2}

![Kaplan--Meier estimates of cause-specific survival (CSS) according to risk group classification in the secondary hormonal therapies-docetaxel (SHTs-DOC) group. CRPC, castration-resistant prostate cancer. \* Statistically significant difference (*P* \< 0.05).](gr3){#fig3}

###### 

Baseline characteristics of the 73 patients with castration-resistant prostate cancer (CRPC).

Table 1

                                         DOC group (*n* = 26)   SHTs-DOC group (*n* = 47)   *P*
  -------------------------------------- ---------------------- --------------------------- --------
  Age (y)                                                                                   
   Median                                68.0                   70.0                        0.3681
   Range                                 39--81                 54--83                      
  Gleason score \> 7 (%)                 83.3                   86.1                        0.7370
  Prior treatment (%)                                                                       
   Alternative anti-androgen             69.2                   89.4                        0.0527
   Antiandrogen withdrawal               84.6                   70.2                        0.2575
  ECOG performance status (%)                                                               
   0--1                                  96.2                   89.4                        0.4118
   2                                     3.8                    10.6                        
  Pain (%)                               34.6                   21.3                        0.2685
  Serum PSA (ng/mL)                                                                         
   Median                                42.0                   26.5                        0.5189
   Range                                 2.24--2379             2.43--924                   
  Anemia, % (Hb \< 12 g/dL)              50.0                   31.0                        0.1319
  ALP (U/L)                                                                                 
   Median                                310                    331                         0.9049
   Range                                 164--4061              146--2789                   
  Extent of disease (%)                                                                     
   Bone metastasis                       73.1                   78.7                        0.5783
   Visceral metastasis                   19.2                   10.6                        0.3140
  PSADT (mo)                             1.04                   1.30                        0.2199
  0.01--7.38                             0.02--10.7                                         
  Time from starting PADT to CRPC (mo)                                                      
   Median                                15.7                   23.3                        0.1313
   Range                                 3.0--134.1             6.1--163.5                  
  Alive (%)                              15.4                   4.3                         0.1775
  Dead (%)                               84.6                   95.7                        
  Cancer/other causes (%)                73.1/11.5              95.7/0                      

ALP, alkaline phosphatase; DOC, docetaxel; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; PADT, primary androgen deprivation therapy; PSA, prostate-specific antigen; PSADT, PSA doubling time; SHTs, secondary hormonal therapies.

###### 

The univariate and multivariate analysis of prognostic factors in the secondary hormonal therapies-docetaxel group.

Table 2

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             *n*   Cox proportional hazard model\   Log-rank test   Cox proportional hazard model\                                  
                                                   (univariate)                                     (multivariate)                                                  
  ------------------------------------------ ----- -------------------------------- --------------- -------------------------------- ---------- ------ ------------ --------
  Age \> 70 y                                47    1.46                             0.78--2.71      0.2318                           0.2272     1.42   0.74--2.74   0.2959

  ECOG performance status 2                  47    0.98                             0.34--2.28      0.9623                           0.9624     0.87   0.25--2.43   0.8072

  Gleason score \> 7                         43    1.00                             0.45--2.68      0.9876                           0.9876                         

  PSA \> 100 ng/mL                           46    0.82                             0.37--1.64      0.5864                           0.5928                         

  PSADT \< 1.3 mo                            43    1.52                             0.81--2.86      0.1902                           0.1857                         

  Anemia (Hb \< 12g/dL)                      42    0.73                             0.39--1.40      0.3450                           0.3410                         

  ALP \> 700 U/mL                            38    1.23                             0.36--3.16      0.7022                           0.6942                         

  Bone metastasis                            47    1.69                             0.82--3.94      0.1611                           0.1781                         

  Visceral metastasis                        47    3.27                             1.09--8.05      0.0365\*                         0.0120\*   1.94   0.49--6.64   0.3274

  Pain                                       47    1.45                             0.81--2.51      0.0638                           0.0451\*   1.90   0.65--5.37   0.2369

  Time from starting PADT to CRPC \< 24 mo   47    0.85                             0.46--1.55      0.5919                           0.5914     0.89   0.47--1.7    0.7294
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALP, alkaline phosphatase; CI, confidence interval; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HR, hazard ratio; PADT, primary androgen deprivation therapy; PSA, prostate-specific antigen; PSADT, PSA doubling time.

\* Statistically significant difference (*P* \< 0.05).
